These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27153114)

  • 1. A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis.
    Yang J; Niu H; Huang Y; Yang K
    PLoS One; 2016; 11(5):e0149185. PubMed ID: 27153114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics.
    Shao C; Dai W; Li H; Tang W; Jia S; Wu X; Luo Y
    PLoS One; 2017; 12(2):e0171676. PubMed ID: 28207831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic effects of
    Xia L; Zhang W; Gao L
    Biomarkers; 2019 Nov; 24(7):700-711. PubMed ID: 31382782
    [No Abstract]   [Full Text] [Related]  

  • 4. Aberrant Methylation of T-cadherin Can Be a Diagnostic Biomarker for Colorectal Cancer.
    Duan BS; Xie LF; Wang Y
    Cancer Genomics Proteomics; 2017; 14(4):277-284. PubMed ID: 28647701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of CDH13 promoter methylation in the carcinogenesis, progression, and prognosis of colorectal cancer: A systematic meta-analysis under PRISMA guidelines.
    Ye M; Huang T; Li J; Zhou C; Yang P; Ni C; Chen S
    Medicine (Baltimore); 2017 Jan; 96(4):e5956. PubMed ID: 28121942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative assessment of the diagnostic role of CDH13 promoter methylation in lung cancer.
    Zhong YH; Peng H; Cheng HZ; Wang P
    Asian Pac J Cancer Prev; 2015; 16(3):1139-43. PubMed ID: 25735345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlations of Promoter Methylation in WIF-1, RASSF1A, and CDH13 Genes with the Risk and Prognosis of Esophageal Cancer.
    Guo Q; Wang HB; Li YH; Li HF; Li TT; Zhang WX; Xiang SS; Sun ZQ
    Med Sci Monit; 2016 Aug; 22():2816-24. PubMed ID: 27506957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis.
    Chen F; Huang T; Ren Y; Wei J; Lou Z; Wang X; Fan X; Chen Y; Weng G; Yao X
    BMC Urol; 2016 Aug; 16(1):52. PubMed ID: 27578166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis.
    Wu L; Wang F; Xu R; Zhang S; Peng X; Feng Y; Wang J; Lu C
    Breast Cancer Res Treat; 2013 Dec; 142(3):619-27. PubMed ID: 24258259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients.
    Widschwendter A; Ivarsson L; Blassnig A; Müller HM; Fiegl H; Wiedemair A; Müller-Holzner E; Goebel G; Marth C; Widschwendter M
    Int J Cancer; 2004 Mar; 109(2):163-6. PubMed ID: 14750164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant promoter methylation of the cadherin 13 gene in serum and its relationship with clinicopathological features of prostate cancer.
    Wang L; Lin YL; Li B; Wang YZ; Li WP; Ma JG
    J Int Med Res; 2014 Oct; 42(5):1085-92. PubMed ID: 25015764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data.
    Jiang Y; Cui L; Chen WD; Shen SH; Ding LD
    PLoS One; 2012; 7(5):e36780. PubMed ID: 22615811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas.
    Toyooka KO; Toyooka S; Virmani AK; Sathyanarayana UG; Euhus DM; Gilcrease M; Minna JD; Gazdar AF
    Cancer Res; 2001 Jun; 61(11):4556-60. PubMed ID: 11389090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of BRCA1 Promoter Methylation with Breast Cancer in Asia: A Meta- Analysis.
    Nindrea RD; Harahap WA; Aryandono T; Lazuardi L
    Asian Pac J Cancer Prev; 2018 Apr; 19(4):885-889. PubMed ID: 29693332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer: A systematic meta-analysis under the guideline of PRISMA.
    Sheng X; Guo Y; Lu Y
    Medicine (Baltimore); 2017 Jul; 96(28):e7476. PubMed ID: 28700487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas.
    Toyooka S; Toyooka KO; Harada K; Miyajima K; Makarla P; Sathyanarayana UG; Yin J; Sato F; Shivapurkar N; Meltzer SJ; Gazdar AF
    Cancer Res; 2002 Jun; 62(12):3382-6. PubMed ID: 12067979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter methylation and polymorphism of E-cadherin gene may confer a risk to prostate cancer: a meta-analysis based on 22 studies.
    Chang Z; Zhou H; Liu Y
    Tumour Biol; 2014 Oct; 35(10):10503-13. PubMed ID: 25056535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant methylation of
    Pu W; Geng X; Chen S; Tan L; Tan Y; Wang A; Lu Z; Guo S; Chen X; Wang J
    J Cancer; 2016; 7(15):2280-2289. PubMed ID: 27994665
    [No Abstract]   [Full Text] [Related]  

  • 19. Association of genetic variants in and promoter hypermethylation of CDH1 with gastric cancer: a meta-analysis.
    Jing H; Dai F; Zhao C; Yang J; Li L; Kota P; Mao L; Xiang K; Zheng C; Yang J
    Medicine (Baltimore); 2014 Oct; 93(19):e107. PubMed ID: 25340495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma.
    Lin YL; Sun G; Liu XQ; Li WP; Ma JG
    J Int Med Res; 2011; 39(1):179-86. PubMed ID: 21672320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.